Brooke Harkness
Corneal and Contact Management · Tigard, ORNPI 1659721280
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $3,300 of the $5,335 with a category attached, or 61.9%. Valley Contax, Inc. accounts for 75.9% of it on its own, with 6 other manufacturers making up the rest. Reporting peaked in 2019 at $4,306 and has fallen 93.2% since, to $291 in 2025.
Across 38 payments — averaging $140.38 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Valley Contax, Inc.$4K
- Coopervision Inc.$342
- Johnson & Johnson Vision Care, Inc.$309
- Alcon$309
- Tarsus Pharmaceuticals, Inc.$147
- Mallinckrodt Hospital Products Inc.$144
- plus $33 from 1 others
What the payments were for
- Consulting fees$60011%
- Speaking & faculty fees$3,30062%
- Travel & lodging$71813%
- Food & beverage$65712%
- Gifts$601%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Valley Contax, Inc. | 10 | $4,049 |
| Coopervision Inc. | 9 | $342 |
| Johnson & Johnson Vision Care, Inc. | 8 | $309 |
| Alcon | 8 | $309 |
| Tarsus Pharmaceuticals, Inc. | 1 | $147 |
| Mallinckrodt Hospital Products Inc. | 1 | $144 |
| Dompe US, Inc. | 1 | $33 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
Too few corneal and contact management providers in Oregonto place this figure against a meaningful peer group, so we don't.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| RestasisCyclosporine | 113 | $75,902 |
| XiidraLifitegrast | 31 | $20,956 |
| Cyclosporine | 53 | $15,150 |
| CequaCyclosporine | 21 | $12,899 |
| Restasis MultidoseCyclosporine | 11 | $11,384 |
| TyrvayaVarenicline Tartrate | 11 | $7,170 |
| Fluorometholone | 79 | $6,066 |
| Doxycycline Hyclate | 53 | $2,156 |
| Prednisolone Acetate | 29 | $1,354 |
| ErythromycinErythromycin Base | 48 | $500 |
| Doxycycline Monohydrate | 27 | $470 |
| Acetylcysteine | 24 | $340 |
| Azithromycin | 13 | $231 |
| MoxifloxacinMoxifloxacin Hcl | 12 | $182 |
| Neomycin-Polymyxin-DexamethNeomycin/Polymyxin B/Dexametha | 14 | $181 |
Paid to pharmacies, not to this prescriber.
Other corneal and contact management in Tigard
- Beth KinoshitaForest Grove$2K
- Jennifer CoyleForest Grove$349
- Gerald CatesSpringfield$319
- Amanda BalsalobreEugene$232
- Phuong lePortland$165
- Paul StasikPortland$86
- Stacey HoinsMedford$63
- Thomas EmersonClackamas$17
- Gerald StarchvickMedford$15
- Diane Robbins LuceBeaverton$13
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.